Pseudo-generic products and barriers to entry in pharmaceutical markets

Review of Industrial Organization

Volumn 25, Issue 1, 2004, Pages 71-86

  Kong, Ying ^a   Seldon, James R ^a  

^a THOMPSON RIVERS UNIVERSITY   (Canada)

Author keywords

Barriers; Deterrence; Pharmaceuticals; Pseudo generics

Indexed keywords

DEMAND ELASTICITY; INCENTIVE; PHARMACEUTICAL INDUSTRY; TECHNOLOGICAL DEVELOPMENT;

EID: 4444336515     PISSN: 0889938X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:REIO.0000040524.32034.04     Document Type: Article

References (22)

1. Bain, J. S. (1956) Barriers to New Competition. Cambridge: Harvard University Press.
2. Congressional Budget Office (1998) How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry. Washington, D.C.: CBO Natural Resources and Commerce Division.
3. Court of Appeal for Ontario (2000) Apotex Inc., Plaintiff/Appellant versus Hoffman La-Roche Limited, Glaxo Wellcome Inc., Pharmacia & Upjohn Inc. and Altimed Pharmaceutical Company Inc. Toronto:Docket: C33172 (December 14) 1-11.
4. Danzon, P M., and L. -W. Chao (2000) 'Does Regulation Drive Out Competition in Pharmaceutical Markets?', The Journal of Law and Economics, 43(2), 311-358.
5. Dixit, A. (1979) 'A Model of Duopoly Suggesting a Theory of Entry Barriers', The Bell Journal of Economics, 10(1), 20-32.
6. Dixit, A. (1980) 'The Role of Investment in Entry Deterrence', Economic Journal, 90, 95-106.
7. Ferrandiz, J. M. (1999) 'The Impact of Generic Goods in the Pharmaceutical Industry', Health Economics 8(7), 599-612.
8. Freudenheim, M. (1992) 'Merck Sets Generic Drug Sales: A Way to Compete When a Patent Is Up', New York Times, (Tuesday, Sept. 8) D1.
9. Grabowski, H., and J. Vernon (1992) 'Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act', Journal of Law and Economics, 35(2), 331-350.
10. Hollis, A. (2001) 'Closing the FDA's Orange Book', Regulation, 24(4), 14-17.
11. Hollis, A. (2002) 'The Importance of Being First: Evidence from Canadian Generic Pharmaceuticals', Health Economics, 11, 723-734
12. Hollis, A. (2003) 'The Anti-Competitive Effects of Brand-Controlled 'Pseudo-Generics' in the Canadian Pharmaceutical Market', Canadian Public Policy, 29(1), 21-32.
13. Komoto, K. (2001) 'Do Profit Rate Differentials Diminish Over Time? A Statistical Analysis of Long-Term Financial Data', NLI Research Institute paper no. 159 (mimeo), pp. 8.
14. Modigliani, F. (1958) 'New Developments on the Oligopoly Front', Journal of Political Economy, 66, 215-232.
15. Morton, F. M. (2000) 'Barriers to Entry, Brand Advertising, and Generic Entry in the US Pharmaceutical Industry', International Journal of Industrial Organization, 18, 1085-1104.
16. Morton, F. M. S. (1999) 'Entry Decisions in the Generic Pharmaceutical Industry', RAND Journal of Economics, 30(3), 421-440.
17. Reinhardt, U. W. (2001) 'Perspectives on the Pharmaceutical Industry', Health Affairs (Sept/Oct) 136-149.
18. Scherer, F. M. (1993) 'Pricing, Profits and Technological Progress in the Pharmaceutical Industry', The Journal of Economic Perspectives, 7(3), 97-115.
19. Spence, F. M. (1977) 'Entry, Investment, and Oligopolistic Pricing', The Bell Journal of Economics, 8, 534-544.
20. Spence, F. M. (1979) 'Investment Strategy and Growth in a New Market', The Bell Journal of Economics, 10, 1-19.
21. Stackelberg, H. (1952) The Theory of the Market Economy, Alan T. Peacock, trans. New York: Oxford University Press, pp. 194-204.
22. Sylos-Labini, P. (1962) Oligopoly and Technical Progress, Cambridge, MAs.: Harvard University Press.